Vitamin B2 & Cancer: How the Vitamin Stabilizes Tumor Cells

Uns auf Google folgen

Researchers have discovered that vitamin B2 appears to stabilize a protective mechanism in tumor cells, preventing cell death. Blocking this process could make cancer cells more vulnerable to treatment.

Vitamins are essential for metabolism and protecting cells from damage, making them a vital part of a healthy diet. Vitamin B2, likewise known as riboflavin, plays key roles in the body, including energy metabolism and cell protection. Now, new research from Würzburg, Germany, reveals a surprising finding: vitamin B2 can also stabilize cancer cells. This protective effect, ironically, may hold therapeutic potential.

Research findings from the Rudolf Virchow Center at the Julius-Maximilians-University of Würzburg show that cancer cells utilize the same protective mechanisms that healthy cells rely on. Weakening this protection could reduce the resilience of tumors, potentially opening new avenues for cancer treatment.

Vitamin B2 Protects Cells – Including Tumor Cells

Vitamin B2, also called riboflavin, is obtained through the diet and is found in dairy products, eggs, meat, and green vegetables. Within cells, it’s converted into a coenzyme called FAD. This molecule helps neutralize harmful oxygen compounds.

A key player in this process is the protein FSP1, which protects cells from a specific form of programmed cell death called ferroptosis. In this process, iron and oxygen reactions attack the cell membrane. If the damage becomes too extensive, the cell dies in a controlled manner. This protection is vital for healthy cells, but cancer cells also exploit it.

“Vitamin B2 plays a crucial role in protecting cancer cells from ferroptosis,” said Vera Skafar, a doctoral candidate in Professor José Pedro Friedmann Angeli’s research group. The same mechanism that protects cells can therefore also stabilize tumors.

Reduced Vitamin Levels Make Tumor Cells Vulnerable

In cell cultures, researchers found that decreasing the amount of vitamin B2 led to a loss of FSP1 stability. The protein broke down, and cancer cells became more susceptible to ferroptosis.

The researchers worked with genetically modified cancer cell lines and observed increased vulnerability with riboflavin deficiency. “However, there is currently no inhibitor that can do this,” Skafar noted, referring to a drug that specifically targets vitamin B2 metabolism. Currently, the results are limited to laboratory studies, with no clinical trials in humans yet conducted.

Lab Conditions Differ Significantly from the Body

One detail from the study is particularly noteworthy. In human blood, the concentration of riboflavin is approximately 10 to 20 nanomoles per liter. In many cell culture media, it’s 500 to 1,000 nanomoles per liter. Cancer cells in the lab, receive a multiple of the amount typically found in the body.

Even small changes in riboflavin levels influence the stability of the FSP1 protein. Researchers describe the availability of vitamin B2 as an important factor for cell membrane repair, with the coenzyme FAD also playing a central role in ensuring FSP1 function and stability.

These connections could explain why results from cell cultures don’t always directly translate to the human body.

A Bacterial Molecule Targets the Protection Specifically

To investigate the mechanism more closely, the team tested a molecule called roseoflavin. It resembles vitamin B2 and is produced by certain bacteria. Cancer cells absorb this substance and incorporate it into their metabolism, altering the function of the protective protein FSP1.

“It was shown that roseoflavin induces ferroptosis at low concentrations,” said study leader Friedmann Angeli. “Our experiments demonstrate the feasibility of this concept.” Very small amounts in the nanomolar range were sufficient to trigger the effect, but it only occurred in cells with a functioning FSP1, suggesting that roseoflavin specifically interferes with this protective mechanism.

A New Approach to Cancer Therapy

The goal of new therapeutic approaches would be not to directly attack cancer cells, but to disable their protective systems. Once FSP1 becomes unstable, the likelihood of ferroptosis increases. Potential strategies include:

• Inhibiting enzymes that convert riboflavin into active cofactors
• Using molecules that resemble vitamin B2 and block FSP1
• Combining existing drugs with ferroptosis-inducing agents

The researchers plan to develop targeted inhibitors and test them in preclinical models.

Ferroptosis Also Plays a Role in Other Diseases

“Ferroptosis is not only relevant to cancer,” explained Friedmann Angeli. Increasingly, evidence suggests that this mechanism may also play a role in neurodegenerative diseases. It is also linked to tissue damage that occurs after organ transplants or severe circulatory disorders.

Knowledge of vitamin B2 metabolism could therefore also be important for other diseases. At the same time, it’s important to note: no one advises avoiding vitamin B2. The body needs riboflavin for central processes in energy metabolism, for cell protection, and for numerous enzymatic reactions.

In summary:

• Vitamin B2 stabilizes the protective protein FSP1 via the coenzyme FAD and helps cancer cells avoid ferroptosis – a special form of cell death.
• If the availability of riboflavin decreases or FSP1 is specifically blocked, tumor cells lose their membrane protection and become much more sensitive to oxidative stress.
• This opens up a new therapeutic approach: not the cancer cell itself is directly attacked, but its internal protective system – a targeted intervention in vitamin B2 metabolism could make tumors vulnerable.